▲ Anti-D-Rh0 immunoglobulin (WinRho SD) is the only virally inactivated polyclonal antibody used in preventing the destruction of antibody/platelet complexes in patients with immune thrombocytopenic purpura (ITP) ▲ Its main mechanism of action appears to be via Fc receptor blockade but immunomodulatory mechanisms have also been postulated ▲ Anti-D-Rh0 immunoglobulin achieved response rates ranging from 62 to 92% in children and adults with ITP ▲ In one nonblinded study of children at risk of cerebral haemorrhage, intravenous IgG achieved a greater response than anti-D-Rh0 immunoglobulin as assessed by increases in platelet counts at 72 hours ▲ Increases in platelet counts were greatest in children and in those who had not undergone splenectomy.